Condition
Atherosclerosis
Atherosclerosis is a slow buildup of fatty plaque in artery walls, driven by cholesterol-carrying particles and inflammation, which narrows and stiffens the vessels. Berberine has the most research behind it, and small studies found lower C-reactive protein, a marker of inflammation; apolipoprotein A went up with niacin, and HDL cholesterol improved with L-carnitine. Still, the evidence is mostly limited, built on small trials, and naringenin's promise came largely from animal work.
Sources: PMID 22085343; PMID 19618992
- Supplements studied
- 14
- Graded outcomes
- 14
- Trials
- 7
- People studied
- 4,749
Evidence by supplement
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Atherosclerosis Risk A review of literature (PMID 25483717) summarizes consistent preclinical evidence that naringenin reduces LDL and triglycerides, increases HDL, suppresses macrophage inflammation, and inhibits foam cell formation. In mice, naringin reduced atherosclerotic plaque by 41% over 18 weeks (PMID 21684135). One human RCT showed reduced arterial stiffness (PMID 26016866), supporting vascular benefit. | Improves (the measure goes down) | Moderate effect | 5 studies | 48 people | ||
Studies that measured atherosclerosis risk | ||||||
Phosphorus
- Vascular Calcification: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Vascular Calcification Mechanistic and observational studies demonstrate that excess phosphorus promotes pathological vascular calcification by inducing osteogenic differentiation of vascular smooth muscle cells. Clinical studies in CKD patients show phosphate burden accelerates arterial calcification and vascular stiffness. | Improves (the measure goes up) | Moderate effect | 4 studies | |||
Studies that measured vascular calcification | ||||||
Niacin (Vitamin B3)
- Apolipoprotein A: improves
- Apolipoprotein B: improves
- Low-density lipoprotein (LDL): improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Apolipoprotein A Small Increase | Improves (the measure goes up) | Small effect | 1 study | 3,196 people | ||
Studies that measured apolipoprotein a | ||||||
| Apolipoprotein B | Improves (the measure goes down) | 3 studies | 3,196 people | |||
Studies that measured apolipoprotein b
| ||||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 2 studies | 3,196 people | |||
Studies that measured low-density lipoprotein (ldl) | ||||||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 1 study | 3,196 people | |||
Studies that measured high-density lipoprotein (hdl) | ||||||
| Heart Attack Risk | Changes; see studies | 3,196 people | ||||
| Stroke Risk | Changes; see studies | 3,196 people | ||||
| Triglycerides | Improves (the measure goes down) | 3,196 people | ||||
Ginkgo Biloba
- Microcirculation: improves
- Oxidative Stress Biomarkers: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Microcirculation Small Improvement | Improves (the measure goes up) | Small effect | 1 study | 32 people | ||
Studies that measured microcirculation | ||||||
| Oxidative Stress Biomarkers | Improves (the measure goes down) | 32 people | ||||
Berberine
- C-Reactive Protein (CRP): improves
- Total cholesterol: improves
- High-density lipoprotein (HDL): improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| C-Reactive Protein (CRP) Small Decrease | Improves (the measure goes down) | Small effect | 120 people | |||
| Total cholesterol | Improves (the measure goes down) | 3 studies | 689 people | |||
Studies that measured total cholesterol
| ||||||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 2 studies | 589 people | |||
| Triglycerides | Improves (the measure goes down) | 1 study | 689 people | |||
Studies that measured triglycerides | ||||||
| Interleukin 6 | Improves (the measure goes down) | 240 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 689 people | ||||
| TNF-Alpha | Improves (the measure goes down) | 240 people | ||||
Policosanol
- High-density lipoprotein (HDL): improves
- Low-density lipoprotein (LDL): improves
- Total cholesterol: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| High-density lipoprotein (HDL) Small Improvement | Improves (the measure goes up) | Small effect | 179 people | |||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 10 studies | 179 people | |||
Studies that measured low-density lipoprotein (ldl) | ||||||
| Total cholesterol | Improves (the measure goes down) | 3 studies | 179 people | |||
Studies that measured total cholesterol
| ||||||
| Triglycerides | Improves (the measure goes down) | 179 people | ||||
Cyanidin
- Endothelial Function: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Endothelial Function In apolipoprotein E-deficient mice, C3G supplementation protected against hypercholesterolemia-mediated endothelial dysfunction, attenuated atherosclerosis, and promoted endothelial repair in diabetic models. In vitro, C3G attenuated angiotensin II-induced oxidative stress in vascular endothelial cells and modulated miR-204-5p/SIRT1-mediated inflammation and apoptosis. No human cardiovascular trials with isolated C3G. | Improves (the measure goes up) | Moderate effect | 6 studies | |||
Studies that measured endothelial function
| ||||||
Chinese Hawthorn
- Atherosclerosis Progression: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Atherosclerosis Progression Network pharmacology and animal pharmacology studies on the Danshen-Shanzha herb pair suggest protective effects against atherosclerosis. A 2026 study demonstrated synergistic promotion of fatty acid oxidation via PPARα, Plin-5, and Plin-2 activation in metabolic liver disease models. | Changes; see studies | Small effect | 3 studies | |||
Studies that measured atherosclerosis progression
| ||||||
Danshen
- Atherosclerosis Progression: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Atherosclerosis Progression In preclinical models, danshen compounds reduce oxidized LDL and inhibit smooth muscle cell hyperplasia after vascular injury (PMID:11367667). Magnesium lithospermate B protects human aortic endothelial cells from free radical damage in vitro (PMID:15250206). Human translation of these anti-atherogenic effects has not been established. | Changes; see studies | Small effect | 2 studies | |||
Flavanols
- LDL Oxidation: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| LDL Oxidation In vitro studies show flavan-3-ols and procyanidins protect liposomes against lipid oxidation and bilayer disruption. Cocoa procyanidins protect LDL from oxidation regardless of polymer chain length when monomer units are controlled, suggesting monomeric flavanols are the active species. | Improves (the measure goes down) | Moderate effect | 2 studies | |||
Hederagenin
- Atherosclerosis Progression: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Atherosclerosis Progression In a Wistar rat atherosclerosis model (high-lipid diet + vitamin D3), hederagenin improved blood rheology and endothelial function, corrected iNOS/eNOS imbalance, and inhibited IKKβ/NF-κB signaling with results comparable to atorvastatin at statistical significance (P < 0.01). | Improves (the measure goes up) | Moderate effect | 1 study | |||
Studies that measured atherosclerosis progression | ||||||
Vitamin C
- Adiponectin
- Triglycerides: improves
- Blood glucose: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Adiponectin No effect | NoneNo effect | 8 people | ||||
| Triglycerides | Improves (the measure goes down) | 5 studies | 8 people | |||
| Blood glucose | Improves (the measure goes down) | 3 studies | 8 people | |||
| Inflammation | Improves (the measure goes down) | 2 studies | 8 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 8 people | |||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 1 study | 8 people | |||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 8 people | ||||
| Insulin | Changes; see studies | 8 people | ||||
| LDL Oxidation | Improves (the measure goes down) | 8 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 8 people |
Nicotinamide Mononucleotide
- Endogenous Advanced Glycation End Products
- Pulse Wave Velocity: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Endogenous Advanced Glycation End Products No effect | NoneNo effect | 36 people | ||||
| Pulse Wave Velocity | Improves (the measure goes down) | 1 study | 36 people |
Key findings
- High-density lipoprotein (HDL)Improves (the measure goes up)
- Atherosclerosis RiskImproves (the measure goes down)
- Vascular CalcificationImproves (the measure goes up)
The Atherosclerosis protocol
2 primary supplements · 4 supporting supplements
- Berberine500 mg three times daily
- Omega-3 Fatty Acids (EPA/DHA)2–4 g EPA/DHA daily
Shop the evidence-backed picks
Support alongside medical care. These supplements are not a treatment for Atherosclerosis. If you are being treated for it, talk to your clinician before adding one: supplements can interact with medicines.
The collection holds the supplements we grade A or B for its theme, in third-party tested products where the catalog has them. It opens in our Fullscript store. You can look through it without signing in; Fullscript asks for a free account to order.
We earn from purchases made in our Fullscript store, and links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Full disclosure
Studies cited
2 studies from PubMed